leuprolide

Summary

Summary: A potent and long acting analog of naturally occurring gonadotropin-releasing hormone (GONADORELIN). Its action is similar to gonadorelin, which regulates the synthesis and release of pituitary gonadotropins.

Top Publications

  1. ncbi Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate
    H B Ravivarapu
    Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, Colorado 80525, USA
    J Pharm Sci 89:732-41. 2000
  2. ncbi Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction
    Mark V Sauer
    Division of Reproductive Endocrinology, College of Physicians and Surgeons, Columbia University, NY, USA
    Reprod Biomed Online 9:487-93. 2004
  3. ncbi Eligard: leuprolide acetate in a novel sustained-release delivery system
    Oliver Sartor
    Stanley S Scott Cancer Center, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
    Urology 61:25-31. 2003
  4. ncbi Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells
    Cristiana Angelucci
    Institute of Histology and Embryology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Itaty
    Anticancer Res 24:2729-38. 2004
  5. ncbi Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells
    G Sica
    Istituto di Istologia ed Embriologia, Facolta di Medicina e Chirurgia, Universita Cattolica del S Cuore, Roma, Italia
    Eur Urol 35:2-8. 1999
  6. ncbi The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients
    Jan Erik Damber
    Institute of Clinical Sciences, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Urology 80:174-80. 2012
  7. pmc Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
    Rajni Sethi
    Department of Radiation Oncology, New York University Langone Medical Center, New York, NY 10016, USA
    Clin Interv Aging 4:259-67. 2009
  8. pmc Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 112:2188-94. 2008
  9. ncbi Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide
    H B Ravivarapu
    Atrix Laboratories, Incorporated, 2579 Midpoint Drive, Fort Collins, CO 80525, USA
    Int J Pharm 194:181-91. 2000
  10. ncbi Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
    Bertrand Tombal
    Cliniques Universitaires Saint Luc Université Catholique de Louvain, Brussels, Belgium
    Eur Urol 57:836-42. 2010

Research Grants

Detail Information

Publications235 found, 100 shown here

  1. ncbi Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate
    H B Ravivarapu
    Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, Colorado 80525, USA
    J Pharm Sci 89:732-41. 2000
    The objective of these studies was to develop a leuprolide acetate depot based on an in situ forming drug delivery system (Atrigel(R)) to suppress the pituitary-gonadal axis and in turn the serum testosterone to chemical castration levels ..
  2. ncbi Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction
    Mark V Sauer
    Division of Reproductive Endocrinology, College of Physicians and Surgeons, Columbia University, NY, USA
    Reprod Biomed Online 9:487-93. 2004
    An open label, randomized, multi-centre study was performed to compare cetrorelix and leuprolide acetate for prevention of premature LH surge and to assess whether patients treated with cetrorelix benefit from addition of recombinant ..
  3. ncbi Eligard: leuprolide acetate in a novel sustained-release delivery system
    Oliver Sartor
    Stanley S Scott Cancer Center, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
    Urology 61:25-31. 2003
    ..Of these approved products, 3 involve different delivery systems for the LHRH superagonist leuprolide acetate...
  4. ncbi Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells
    Cristiana Angelucci
    Institute of Histology and Embryology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Itaty
    Anticancer Res 24:2729-38. 2004
    ..In addition, experiments aimed to evaluate the action of the analogue on apoptosis were performed...
  5. ncbi Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells
    G Sica
    Istituto di Istologia ed Embriologia, Facolta di Medicina e Chirurgia, Universita Cattolica del S Cuore, Roma, Italia
    Eur Urol 35:2-8. 1999
    ..We investigated modulation of cell growth and prostate-specific antigen (PSA) gene expression in prostatic cancer cells by the luteinizing hormone-releasing hormone analog (LH-RHa), leuprorelin acetate, alone or combined with other agents...
  6. ncbi The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients
    Jan Erik Damber
    Institute of Clinical Sciences, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Urology 80:174-80. 2012
    To investigate the effects of baseline testosterone on testosterone control and prostate-specific antigen (PSA) suppression using data from a phase III trial (CS21) comparing degarelix and leuprolide in prostate cancer.
  7. pmc Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
    Rajni Sethi
    Department of Radiation Oncology, New York University Langone Medical Center, New York, NY 10016, USA
    Clin Interv Aging 4:259-67. 2009
    ....
  8. pmc Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 112:2188-94. 2008
    ..To the authors' knowledge, however, less is known regarding the effects of GnRH agonists on other attributes of the metabolic syndrome...
  9. ncbi Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide
    H B Ravivarapu
    Atrix Laboratories, Incorporated, 2579 Midpoint Drive, Fort Collins, CO 80525, USA
    Int J Pharm 194:181-91. 2000
    ..study was to evaluate the formulation parameters critical to the efficacy of an injectable polymeric implant of leuprolide acetate, formed in situ, in suppressing and maintaining serum testosterone levels of animals in the range 0...
  10. ncbi Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
    Bertrand Tombal
    Cliniques Universitaires Saint Luc Université Catholique de Louvain, Brussels, Belgium
    Eur Urol 57:836-42. 2010
    ..Recent data suggest prostate-specific antigen (PSA) progression may predict overall survival in prostate cancer patients...
  11. ncbi Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition
    Matthew R Smith
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 22:2546-53. 2004
    ..Less is known about the effects of bicalutamide monotherapy on bone mineral density and body composition...
  12. ncbi Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems
    Xiaosong Luan
    College of Pharmacy, Freie Universitat Berlin, Kelchstr 31, 12169 Berlin, Germany
    J Control Release 110:266-72. 2006
    ..the influence of poly(lactide-co-glycolide) (PLGA) type (molecular weight and end-group functionality) on the leuprolide release from in situ forming microparticle (ISM) systems...
  13. ncbi Chitosan-coated liposomes: characterization and interaction with leuprolide
    J Guo
    Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
    Int J Pharm 260:167-73. 2003
    ..concentration and lipid type on the characteristics of chitosan-coated liposomes and their interactions with leuprolide. Liposomes from lipid of high purity and low purity were prepared and coated by chitosan...
  14. ncbi Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
    Fritz H Schroder
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BJU Int 106:182-7. 2010
    ..1b OBJECTIVE To compare the activity of degarelix, a new gonadotrophin-releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S-ALP) levels in patients with prostate cancer...
  15. pmc Hormonal induction of gamete release, and in-vitro fertilisation, in the critically endangered southern corroboree frog, Pseudophryne corroboree
    Phillip G Byrne
    School of Biological Sciences, Monash University, Melbourne, Victoria, Australia
    Reprod Biol Endocrinol 8:144. 2010
    ....
  16. ncbi In vivo evaluation and in vitro metabolism of leuprolide in mice--mass spectrometry-based biomarker measurement for efficacy and toxicity
    Zacharias D Sofianos
    Division of Pharmacology Pharmacotechnology, Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece
    J Mass Spectrom 43:1381-92. 2008
    ..A mass spectrometry-based approach was developed and applied towards the measurement of leuprolide, a peptide drug for the treatment of prostate cancer, in mouse plasma...
  17. ncbi Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases
    R B Krueger
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Arch Sex Behav 30:409-22. 2001
    ..This paper reports the results of treatment using a depot suspension of leuprolide acetate on 12 patients with paraphilic disorders or with sexual disorders not otherwise specified to suppress or ..
  18. ncbi In vivo transdermal delivery of leuprolide using microneedles and iontophoresis
    Vishal Sachdeva
    Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30341, USA
    Curr Pharm Biotechnol 14:180-93. 2013
    ..of this study was to investigate the use of iontophoresis and/or microneedles to enhance transdermal delivery of leuprolide acetate in vivo in hairless rats...
  19. ncbi Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy
    V M Jasonni
    Departments of Obstetrics and Gynaecology, University of Modena and Reggio Emilia, Modena, Italy
    Acta Obstet Gynecol Scand 80:956-8. 2001
    ..METHOD: Twenty patients received long-term GnRHa administration, six monthly depot injections of leuprolide acetate (LA), while 16 patients were treated with two monthly LA injections before surgery...
  20. ncbi Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer
    C F Heyns
    Department of Urology, University of Stellenbosch, Tygerberg Hospital, Western Cape, South Africa
    BJU Int 92:226-31. 2003
    ..the efficacy of monthly administrations of the luteinizing hormone-releasing hormone agonists triptorelin pamoate and leuprolide acetate to induce and maintain castrate levels of serum testosterone in men with advanced prostate cancer.
  21. ncbi Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial
    T Strowitzki
    Department of Gynecological Endocrinology and Reproductive Medicine, University of Heidelberg, Vossstrasse 9, 69115 Heidelberg, Germany
    Hum Reprod 25:633-41. 2010
    ..The current non-inferiority trial compared the efficacy and safety of dienogest against leuprolide acetate (LA) for treating the pain associated with endometriosis.
  22. ncbi Pituitary apoplexy after leuprolide injection for ovum donation
    Gregory Engel
    Department of Internal Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    J Adolesc Health 32:89-93. 2003
    ..We describe a case of pituitary apoplexy in a young woman receiving leuprolide in preparation for ovum donation...
  23. ncbi Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women
    Miglena Grigorova
    Department of Psychology, McGill University, Montreal, Canada
    Psychoneuroendocrinology 31:935-47. 2006
    ..Twenty-five women were treated with leuprolide acetate depot (LAD), a gonadotropin releasing hormone (GnRH) analog that chemically suppressed ovarian function ..
  24. ncbi Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial
    Guiping Song
    Department of Pharmacy, Jiangyin Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Jiangyin, Jiangsu, China
    Med Oncol 30:667. 2013
    ..This study was designed to examine the efficacy of leuprolide acetate on ovarian function preservation in patients with breast cancer...
  25. ncbi Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits
    Somnath Singh
    Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University Medical Center, Omaha, NE 68178, USA
    Int J Pharm 328:42-8. 2007
    b>Leuprolide acetate (LA) is a synthetic analog of gonadotropin releasing hormone. It is effective in prostate cancer treatment only when its desired concentration in blood is maintained for longer duration...
  26. ncbi Pituitary apoplexy after leuprolide
    Anu Davis
    University of Texas Health Science Center Houston, 6431 Fannin, MSB 4 202, Houston, TX 77030, USA
    Pituitary 9:263-5. 2006
    ..advanced prostate cancer who presented with an acute picture of pituitary apoplexy after his first dose of leuprolide. He developed headache and neck pain within a few hours of treatment followed by nausea, vomiting, ptosis and ..
  27. ncbi Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study
    Dalsan You
    Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    Scand J Urol Nephrol 44:399-405. 2010
    To investigate the impacts of leuprolide acetate on the quality of life (QoL) of patients with prostate cancer.
  28. ncbi A functioning FSH-secreting pituitary macroadenoma causing an ovarian hyperstimulation syndrome with multiple cysts resected and relapsed after leuprolide in a reproductive-aged woman
    Enrico Macchia
    Department of Endocrinology, University of Pisa, Pisa, Italy
    Gynecol Endocrinol 28:56-9. 2012
    ..and high serum estradiol was submitted to the resection of ovarian cysts and then treated with long-acting leuprolide 11.25 mg...
  29. ncbi Leuprolide acetate suppresses pedophilic urges and arousability
    Justine M Schober
    Hamot Medical Center, Erie, PA 16507, USA
    Arch Sex Behav 34:691-705. 2005
    Cognitive-behavioral psychotherapy was compared with cognitive-behavioral psychotherapy augmented by leuprolide acetate (LA) for suppression of pedophilic behavior...
  30. ncbi Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer
    Walid Massoud
    Department of Urology, Lyon Sud Hospital, Lyon, France
    Int J Urol 13:87-8. 2006
    ..Gonadotropin-releasing hormone antagonists (abarelix), by avoiding the flare-up reaction, might be used in such instances...
  31. ncbi GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors
    Cristiana Angelucci
    Institute of Histology and Embryology, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168, Rome, Italy
    Endocrine 36:87-97. 2009
    ....
  32. ncbi In vitro transdermal iontophoretic delivery of leuprolide under constant current application
    Charu Kochhar
    Institute of Pharmaceutical Technology, University of Basel, Klingelbergstrasse 50, 4056, Switzerland
    J Control Release 98:25-35. 2004
    Transdermal delivery of Leuprolide, a nonapeptide LHRH agonist, was studied using constant current iontophoresis to explore methods for improving iontophoretic efficiency and determine the feasibility of delivery of therapeutic doses of ..
  33. ncbi Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty
    Shrikrishna V Acharya
    Department of Endocrinology, K E M Hospital, Parel, Mumbai 12, Maharashta, India
    Pituitary 12:335-8. 2009
    To determine utility of luteinizing hormone (LH) estimation, post intramuscular (IM) depot leuprolide in comparison with subcutaneous leuprolide stimulation test...
  34. ncbi Direct effects of GnRH agonists in human hormone-sensitive endometrial cells
    G Sica
    Istituto di Istologia ed Embriologia, Facolta di Medicina e Chirurgia, Universita Cattolica del Sacro Cuore, Largo F Vito, 1, 00168 Rome, Italy
    Mol Cell Endocrinol 176:121-8. 2001
    ..Our data provide evidence that GnRH agonists can directly inhibit estrogen-stimulated endometrial cancer cell growth and suggest that they may interfere with steroid-receptor machinery...
  35. ncbi Characterization of the solution conformations of leuprolide acetate
    J D Meyer
    Center for Pharmaceutical Biotechnology, University of Colorado Health Sciences Center, Denver, USA
    J Pept Res 60:159-68. 2002
    b>Leuprolide acetate (pGlu-His-Trp-Ser-Tyr-d-Leu-Leu-Arg-Pro-NHEt), a potent LHRH agonist in wide clinical use, was characterized conformationally by NMR and circular dichroism...
  36. ncbi Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells
    Fortunata Iacopino
    Istituto di Istologia ed Embriologia, Facolta di Medicina e Chirurgia, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy
    Int J Oncol 29:237-47. 2006
    ....
  37. pmc Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics
    Steven M Pincus
    J Psychiatr Res 45:386-94. 2011
    ..women with premenstrual dysphoric disorder (PMDD) show symptomatic improvement in response to the GnRH agonist leuprolide acetate, which suppresses ovarian function...
  38. ncbi [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study]
    I Ouzaid
    Service d urologie et de transplantation rénale, Hopital de la Pitie Salpetriere, AP HP, Universite Pierre et Marie Curie, Universite Paris VI, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Prog Urol 21:866-74. 2011
    Androgen-deprivation therapy modalities are on continuing evolution. Leuprolide Acetate (LA) Eligard(®)45mg was the first 6-monthly LHRH agonist (agoniste luteinizing hormone-releasing hormone [LHRHa]) treatment available for use in ..
  39. ncbi Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma
    Arthur J Castelbaum
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6149, USA
    Fertil Steril 78:1311-3. 2002
    ..To report a case of a gonadotroph adenoma diagnosed after a dramatic increase in estradiol level and ovarian hyperstimulation in response to a gonadotropin-releasing hormone agonist...
  40. ncbi Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer
    Yannis Guerra
    Hospital of Cook County Rush University Medical Center, Chicago, IL, USA
    Pituitary 13:54-9. 2010
    ..of headache and blurry vision--that progressed to left ophthalmoplegia and ptosis--after receiving a dose of leuprolide for Prostate cancer therapy. Imaging showed a hemorrhagic sellar mass...
  41. pmc A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
    Ulf W Tunn
    Urological Clinic Facharztzentrum Klinikum Offenbach, Starkenburgring 50, 63069 Offenbach Main, Germany
    BMC Urol 11:15. 2011
    Testosterone stimulates growth in many prostate tumours. The established GnRH analogue leuprolide acetate is incorporated in a novel biodegradable polymer matrix (Atrigel® delivery system), that can be administered to reduce testosterone ..
  42. ncbi Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide
    Javed Iqbal
    Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Josef Moller Haus, Innsbruck, Austria
    Eur J Pharm Biopharm 80:95-102. 2012
    The aim of the present study was to develop an oral delivery system for the peptide drug leuprolide. Gel formulations based on unmodified chitosan/reduced glutathione (GSH) and chitosan-thioglycolic acid (chitosan-TGA)/GSH were prepared, ..
  43. ncbi A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders
    Andrea J DiLuigi
    Center for Advanced Reproductive Services, University of Connecticut Heath Center, Farmington, Connecticut 06030 6224, USA
    Fertil Steril 95:2531-3. 2011
    We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the ..
  44. ncbi Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer
    J De La Rosette
    AMC University Hospital Urology, Amsterdam, The Netherlands
    Int J Clin Pract 65:559-66. 2011
    To evaluate whether switching prostate cancer (PCa) patients from leuprolide to degarelix is associated with any change in the efficacy of testosterone suppression or safety profile during the first 3 months.
  45. ncbi Leuprorelin acetate affects adhesion molecule expression in human prostate cancer cells
    Cristiana Angelucci
    Institute of Histology and Embryology, School of Medicine, Catholic University of the Sacred Heart, I 00168 Rome, Italy
    Int J Oncol 38:1501-9. 2011
    ....
  46. ncbi Modifying the release of leuprolide from spray dried OED microparticles
    R Alcock
    Elan Drug Delivery Limited, 1 Mere Way, Ruddington, NG11 6JS, Nottingham, UK
    J Control Release 82:429-40. 2002
    ..The synthetic hormone analogue, leuprolide, was encapsulated within these matrices using hydrophobic ion pairing and solvent spray drying...
  47. ncbi In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters
    Xiaosong Luan
    College of Pharmacy, Freie Universitat Berlin, Kelchstr 31, 12169 Berlin, Germany
    Eur J Pharm Sci 27:143-9. 2006
    The objective of present study was to control the delivery of leuprolide acetate using in situ forming microparticle (ISM) systems...
  48. ncbi A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer
    Ramon Perez-Marrero
    Urology Health Center, New Port Richey, FL 34652, USA
    Expert Opin Pharmacother 5:447-57. 2004
    ..e., hormone therapy). LHRH analogues (e.g., leuprolide acetate) desensitise and downregulate pituitary LHRH receptors, thus reducing LH synthesis and release...
  49. ncbi A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders
    David W Schmidt
    The Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Connecticut Health Center, Farmington, Connecticut 06030 6224, USA
    Fertil Steril 83:1568-71. 2005
    ....
  50. ncbi Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome
    Stefano Palomba
    Department of Obstetrics and Gynecology, University Magna Graecia of Catanzaro, Via Nicolardi 188, Naples 80131, Italy
    Fertil Steril 83:1012-20. 2005
    ..To evaluate the effectiveness of gonadotropin-releasing hormone agonists (GnRH-a) with or without coadministration of tibolone in women with menstrual cycle-related irritable bowel syndrome (IBS)...
  51. ncbi Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study
    R L Rosenfield
    University of Chicago, Pritzker School of Medicine, Department of Pediatrics, Illinois 60637 1470, USA
    J Clin Endocrinol Metab 81:3408-11. 1996
    ..Since nafarelin injection is no longer produced, studies were conducted to determine the dosage of leuprolide that would yield equivalent responses...
  52. ncbi A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty
    Kimberly Fuld
    Drexel University College of Medicine, Philadelphia, PA, USA
    J Pediatr 159:982-7.e1. 2011
    To compare 1-month and 3-month depot formulations of leuprolide acetate (DL), a gonadotropin-releasing hormone analog, in the treatment of central precocious puberty (CPP).
  53. ncbi A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer
    E David Crawford
    Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado 80045, USA
    J Urol 186:889-97. 2011
    We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial.
  54. pmc Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant
    H B Ravivarapu
    Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525, USA
    AAPS PharmSciTech 1:E1. 2000
    The primary objective of this study was to evaluate the effect of drug loading on the release of leuprolide acetate from an injectable polymeric implant, formed in situ, and efficacy of the released drug in suppressing serum testosterone ..
  55. ncbi Ulipristal acetate versus leuprolide acetate for uterine fibroids
    Jacques Donnez
    Cliniques Universitaires Saint Luc Catholic University of Louvain, Brussels, Belgium
    N Engl J Med 366:421-32. 2012
    The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear.
  56. ncbi Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist
    Satoshi Ichigo
    Department of Obstetrics and Gynecology, Matsunami General Hospital, Gifu 501 6062, Japan
    Arch Gynecol Obstet 284:667-70. 2011
    ..Aim of this study was to examine and compare the efficacy of gonadotropin-releasing hormone agonist (GnRHa) versus dienogest in premenopausal women with uterine myoma...
  57. ncbi Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization
    Gul Shahnaz
    Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 52c, Josef Moller Haus, 6020 Innsbruck, Austria
    Int J Pharm 428:164-70. 2012
    ..of this study was to develop thiolated nanoparticles to enhance the bioavailability for the nasal application of leuprolide. Thiolated chitosan-thioglycolic acid (chitosan-TGA) and unmodified chitosan nanoparticles (NPs) were developed ..
  58. ncbi Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome
    Robert L Gustofson
    Reproductive Endocrinology and Infertility, NIH, Bethesda, MD, USA
    Hum Reprod 21:2830-7. 2006
    ..Since GnRH antagonist is associated with a reduction in E(2) levels, we hypothesized that GnRH-antagonist treatment of women down-regulated with GnRH agonist who are at risk of OHSS might reduce E(2) levels and avoid cycle cancellation...
  59. ncbi Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer
    J Guo
    Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009
    Int J Pharm 278:415-22. 2004
    The purpose of this study was to investigate the transport mechanisms and causes of low bioavailability of leuprolide. The everted gut sac technique and Caco-2 cell monolayer were used to examine: (1) transport properties, enzyme ..
  60. ncbi Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection
    Huseyin Demirbilek
    Division of Pediatric Endocrinology, Hacettepe University Medical School, Ankara, Turkey
    Clin Endocrinol (Oxf) 76:126-30. 2012
    ....
  61. ncbi Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide
    P Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    Prostate Cancer Prostatic Dis 14:184-90. 2011
    ..c., 240/80 mg, n=207, or 240/160 mg, n=202) or leuprolide (i.m., 7.5 mg, n=201) for 12 months...
  62. ncbi Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Michael C Cox
    Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bldg 10, Rm 5A01, MSC 1910, Bethesda, MD 20892, USA
    Expert Rev Anticancer Ther 5:605-11. 2005
    ..Based on the need for improved convenience of administration, a novel formulation of leuprolide acetate (Eligard; Atrix Laboratories Inc...
  63. ncbi Leuprolide-induced myopathy
    Jay A Van Gerpen
    J Am Geriatr Soc 50:1746. 2002
  64. pmc Delayed oral estradiol combined with leuprolide increases endometriosis-related pain
    B S Hurst
    Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Denver, USA
    JSLS 4:97-101. 2000
    ..To determine if low-dose estrogen replacement can be added to GnRH agonist therapy after three months to reduce hypoestrogenic symptoms while allowing continued relief of pain in patients with endometriosis...
  65. ncbi Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results
    Veronica Mericq
    Institute of Maternal and Child Research, Faculty of Medicine, University of Chile, Casilla 226 3, Santiago, Chile
    Clin Endocrinol (Oxf) 71:686-90. 2009
    ..The goal of our study was to compare the efficacy of three leuprolide acetate (LA) preparations, suppressing gonadotropin secretion in patients with CPP.
  66. ncbi Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems
    W Y Dong
    College of Pharmacy, Freie Universitat Berlin, Kelchstrasse 31, 12169 Berlin, Germany
    J Control Release 115:158-67. 2006
    ..The chemical stability of PLGA and the drug is a major concern. In this study, the stability of PLGA and leuprolide acetate in the in-situ forming systems and lyophilized sponges was investigated...
  67. ncbi Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group
    M D Hornstein
    Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Obstet Gynecol 91:16-24. 1998
    To evaluate the efficacy and safety of a GnRH agonist, leuprolide acetate depot, alone and in combination with three hormonal add-back regimens in the management of endometriosis-associated pelvic pain.
  68. ncbi Ovarian hyperstimulation syndrome associated with the use of the gonadotropin-releasing hormone agonist leuprolide acetate
    K Droesch
    Department of Obstetrics and Gynecology, State University of New York at Stony Brook 11794 8091
    Fertil Steril 62:189-90. 1994
    ..It is possible that this patient with multiple ovarian cysts, each 2 to 3 cm in size, is at increased risk for a paradoxical stimulatory rather than inhibitory response to GnRH-a...
  69. ncbi Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer
    Olav Erich Yri
    Department of Oncology, Rikshospitalet Radiumhospitalet Health Enterprise, Montebello, 0310 Oslo, Norway
    Eur Urol 49:54-8; discussion 58. 2006
    ..In a cross-sectional, retrospective, non-randomised study to investigate the possibility that some patients treated with luteinizing hormone releasing hormone analogues (LHRH analogues) fail to reach castration levels of serum testosterone...
  70. ncbi A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls
    Vinicius N Brito
    Hospital das Clínicas Faculdade de Medicina da Universidade de Sao Paulo, Disciplina de Endocrinologia e Metabologia, Avenue Dr Eneas de Carvalho Aguiar, 155 2 degrees andar Bloco 6, 05403900, Sao Paulo SP, Brazil
    J Clin Endocrinol Metab 89:4338-42. 2004
    ..The aim of this study was to determine the hormonal parameters for monitoring the adequacy of depot leuprolide acetate treatment in girls with clinical and hormonal diagnosis of gonadotropin-dependent precocious puberty...
  71. ncbi Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression
    N Chegini
    Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Mol Hum Reprod 8:1071-8. 2002
    ..Leiomyoma and myometrial smooth muscle cells (LSMC and MSMC) were isolated and exposed to GnRH agonist (leuprolide acetate, LA), 17beta-estradiol (E2), medroxyprogesterone acetate (MPA), GnRH antagonist (Antide), estrogen ..
  72. ncbi Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study
    Michael Marberger
    Department of Urology, Vienna University Medical School, Vienna, Austria
    Clin Ther 32:744-57. 2010
    A microencapsulated, sustained-release formulation of leuprolide acetate 3.75 mg has been developed.
  73. ncbi Leuprolide stimulation testing for the evaluation of early female sexual maturation
    Anpalakan Sathasivam
    Pediatric Endocrinology and Diabetes, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Endocrinol (Oxf) 73:375-81. 2010
    ..Low concentrations of serum LH and/or oestradiol (E(2)) in girls with early physical signs of precocious puberty pose a diagnostic challenge...
  74. ncbi Hetero-stereocomplexes of D-poly(lactic acid) and the LHRH analogue leuprolide. Application in controlled release
    Joram Slager
    Department of Medicinal Chemistry and Natural Products, Faculty of Medicine, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel
    Eur J Pharm Biopharm 58:461-9. 2004
    ..complexes were obtained by mixing acetonitrile solutions of enantiomeric D-poly(lactic acid) (d-PLA) and leuprolide, an L-configured nonapeptide LHRH analogue...
  75. ncbi Comparison of artificial neural network and multiple linear regression in the optimization of formulation parameters of leuprolide acetate loaded liposomes
    N Arulsudar
    New Drug Delivery Systems Laboratory, Pharmacy Department, M S University of Baroda, Vadodara, India
    J Pharm Pharm Sci 8:243-58. 2005
    ..optimize the effect of formulation variables on the percent drug entrapment (PDE) of the liposomes encapsulating leuprolide acetate by reverse phase evaporation method using Artificial neural network (ANN) and Multiple linear regression ..
  76. ncbi The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, ON, Canada
    BJU Int 102:1531-8. 2008
    ..the efficacy and safety of degarelix, a new gonadotrophin-releasing hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining testosterone suppression in a 1-year phase III trial involving patients with ..
  77. ncbi Leuprolide acetate plus aromatase inhibition for male breast cancer
    Sharon H Giordano
    J Clin Oncol 24:e42-3. 2006
  78. ncbi Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment
    Felipe Herranz Amo
    Urology Service, University General Hospital Gregorio Marañon, Madrid, Spain
    Arch Esp Urol 63:275-81. 2010
    ..To perform comparative analysis of the efficacy and the safety of six months formulation of LHRH analogues indicated for prostate cancer treatment...
  79. ncbi Clinical pharmacokinetics of depot leuprorelin
    Piero Periti
    Department of Preclinical and Clinical Pharmacology, Universita di Firenze, Via XX Settembre 104, 50129 Florence, Italy
    Clin Pharmacokinet 41:485-504. 2002
    ..In general, regular or depot leuprorelin treatment is well tolerated. Local reactions are more common after application of the 3- or 4-month depot in comparison with the 1-month depot...
  80. ncbi Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals
    S Greil
    Department of Surgery, Section Urology and Department of Internal Medicine, St Joseph Mercy Hospital, Ann Arbor, Michigan 48106, USA
    Urology 73:631-4. 2009
    ..the duration of serum testosterone and prostate-specific antigen suppression after each dose of a 4-month depot leuprolide acetate for 18 months and to assess the potential for using serum testosterone as a guide for redosing the ..
  81. ncbi Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas
    Stefano Palomba
    Department of Obstetrics and Gynecology, University Magna Graecia of Catanzaro, Catanzaro, Italy
    Fertil Steril 90:165-73. 2008
    ..To investigate the effects of tibolone co-administration with GnRH agonist treatment in terms of cognition, mood, and quality of life...
  82. ncbi Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain
    P G Crosignani
    I Clinica Ostetrica e Ginecologica Università di Milano, Via Commenda 12 20122 Milano, Italy
    Hum Reprod 21:248-56. 2006
    A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain.
  83. ncbi Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma
    Enrique Castellón
    Physiology and Biophysics Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
    Cancer Invest 24:261-8. 2006
    ..We addressed the issue studying the effect of leuprolide (agonist) and cetrorelix (antagonist) on cell growth, apoptosis and GnRH receptor expression using a primary ..
  84. pmc Effects of luteinizing hormone-releasing hormone and arginine-vasotocin on the sperm-release response of Günther's Toadlet, Pseudophryne guentheri
    Aimee J Silla
    School of Animal Biology, The University of Western Australia, Perth, Australia
    Reprod Biol Endocrinol 8:139. 2010
    ....
  85. ncbi Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injections sites
    M Saxby
    BJU Int 91:125. 2003
  86. ncbi Novel O-palmitoylscleroglucan-coated liposomes as drug carriers: development, characterization and interaction with leuprolide
    M Carafa
    Dept Scienze del Farmaco, University G D Annunzio, Via dei Vestini, 66100 Chieti, Italy
    Int J Pharm 325:155-62. 2006
    ..b>Leuprolide, a synthetic superpotent agonist of luteinizing hormone releasing hormone (LHRH) receptor, was chosen as a model ..
  87. ncbi Prolongation of growth by treatment of 11-hydroxylase deficiency with depot-leuprolide, growth hormone, and hydrocortisone
    Laura J Chalmers
    Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    J Pediatr Endocrinol Metab 19:1251-5. 2006
    ..known hypothalamic priming resulting in early pubertal development could be averted by delaying puberty with leuprolide; also that effects of hydrocortisone and leuprolide on attenuating growth could be counteracted by growth ..
  88. ncbi Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles
    M Isikoglu
    Antalya IVF, 07080 Antalya, Turkey
    Hum Reprod 22:1657-61. 2007
    ..88 mg) reduced dose with a daily low dose (0.5 mg/day) of leuprolide for pituitary suppression as part of controlled ovarian hyperstimulation (COH) in an ICSI program.
  89. ncbi 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Mass 02215, USA
    JAMA 292:821-7. 2004
    ....
  90. pmc Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
    James L Gulley
    Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 180:1432-7; discussion 1437. 2008
    ..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy...
  91. ncbi Leuprorelin acetate granulomas: case reports and review of the literature
    K Yasukawa
    Department of Dermatology, National Hospital Organization Hokkaido Cancer Centre, Sapporo, Hokkaido, Japan
    Br J Dermatol 152:1045-7. 2005
    ..Dermatologists need to know that depot leuprorelin acetate may cause a granulomatous reaction which produces a subcutaneous nodule that might be misdiagnosed as a malignant tumour...
  92. ncbi Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion
    Jack Y Zheng
    Global Pharmaceutical R and D, Formulation Development Center, Abbott Laboratories, North Chicago, IL 60064 6246, USA
    Int J Pharm 307:209-15. 2006
    Studies were conducted to develop oral leuprolide microemulsions using oleic acid as an absorption enhancer and to evaluate its absorption and pharmacological responses in rats...
  93. pmc A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note
    Aliasgar Shahiwala
    Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan, M S University of Baroda, Vadodara 390 001, Gujarat, India
    AAPS PharmSciTech 6:E482-6. 2005
  94. ncbi Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe
    U W Tunn
    Urological Department, Städtisches Klinikum, Offenbach, Germany
    Prostate Cancer Prostatic Dis 12:83-7. 2009
    ..25 mg leuprorelin acetate in the treatment of prostate cancer...
  95. ncbi A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
    The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer.
  96. ncbi A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer
    John Trachtenberg
    Princess Margaret Hospital, Toronto, Canada
    J Urol 167:1670-4. 2002
    ....
  97. ncbi Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain
    William D Schlaff
    University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Fertil Steril 85:314-25. 2006
    To compare the efficacy and safety of SC depot medroxyprogesterone acetate (DMPA-SC 104) with that of leuprolide acetate in treatment of endometriosis.
  98. ncbi Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain
    Mohamed A Bedaiwy
    Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Toronto, and the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Fertil Steril 86:220-2. 2006
    ..One patient stopped her treatment on two occasions to conceive and was successful each time with delivery of a normal baby. No patient had return of pelvic pain after HT add-back...
  99. pmc Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males
    Jason H Mateika
    Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Physiol 561:637-46. 2004
    ..In response to treatment with leuprolide acetate, the threshold measured in wakefulness decreased during carbon dioxide rebreathing in the presence of ..
  100. ncbi Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate
    U Sungurtekin
    Sydney IVF Center, New South Wales, Australia
    Fertil Steril 63:663-5. 1995
    To compare levels of serum LH during continued use of leuprolide acetate (LA) with levels during the first week after discontinuing LA.
  101. pmc Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide
    I Noci
    Department of Gynaecology, Perinatal Medicine and Human Reproduction, University of Florence, Viale G B Morgagni 85, 50134, Firenze, Italy
    Br J Cancer 85:333-6. 2001
    We report here a case of a patient affected by endometrial cancer and treated primarily with leuprolide, the surgical approach being unfeasible due to her compromised conditions...

Research Grants62

  1. RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease
    WILLIAM J MC CUNE; Fiscal Year: 2012
    ..The proposed clinical trial will evaluate the ability of a drug (leuprolide acetate, which is a gonadotropin-releasing hormone agonist) to protect ovaries in patients receiving a specific ..
  2. Excess androgen production in overweight pubertal girls--precursor to PCOS
    CHRISTINE MICHELE BURT SOLORZANO; Fiscal Year: 2013
    ..Aim 2 will use low-dose hydrocortisone and leuprolide therapy to test whether short-term suppression of adrenocorticotropin or gonadotropin production can reduce ..
  3. CONTROLLED RELEASE OF MACROMOLECULES
    ROBERT SAMUEL LANGER; Fiscal Year: 2013
    ..Therefore, we propose to develop combinatorial libraries of new materials with the specific goal of generating clinically useful, non-viral methods for gene therapy. ..
  4. Hot Flash Research Tool for Broad Population Research Studies
    GARY D HAVEY; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: The proposed project develops technology for researchers studying hot flashes in men and women. ..
  5. OVARIAN STEROIDS AND CALCIUM HOMEOSTASIS
    NEIL BRESLAU; Fiscal Year: 1991
    ..Chronic administration of the GnRH analogue leuprolide has been shown to suppress gonadotropins and ovarian steroids to castrate levels...
  6. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2006
    ..will combine basic and applied research to characterize the female response to four ovarian cycle inhibitors: 1) leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) ..
  7. Treatment of Endometriosis-Associated Pelvic Pain
    David Guzick; Fiscal Year: 2007
    ..The only FDA approved 12-month treatment for endometriosis-associated pain is a combination of leuprolide acetate (a GnRH analog), 11.25 mg IM q 12 weeks, and norethindrone acetate, 5 mg PO daily...
  8. Targeting Stealth Liposome for Cancer Gene Therapy
    Esther Chang; Fiscal Year: 2002
    ..These agents have combined annual sales of $1.7 billion, despite the fact that they are merely palliative. ..
  9. CONTROLLED RELEASE OF ATRIAL NATRIURETIC FACTOR
    Maria Rupnick; Fiscal Year: 2001
    ..End of Abstract) ..
  10. REPRODUCTIVE PHYSIOLOGY OF OVARIAN FAILURE
    Nanette Santoro; Fiscal Year: 1992
    ..All 3 agents selected: estradiol, GnRH agonist (leuprolide acetate), and corticosteroids (prednisone) have been previously suggested , in uncontrolled reports, to increase ..
  11. ENVIRONMENTAL/INDUSTRIAL TOXICANTS AND TESTICULAR INJURY
    Kim Boekelheide; Fiscal Year: 2003
    ..Second, irreversible injury can be rescued by lowering the intratesticular testosterone concentration with leuprolide. Three Specific Aims are designed to exploit this new information as follows: 1) using the Fas ligand deficient ..
  12. Ovarian Hormone Suppression, Cognition, and Mood
    Lisa Cox; Fiscal Year: 2005
    ..The proposed study will investigate the effects of a 3-month intervention period of leuprolide acetate on cognitive function and mood to accomplish the following specific aims: 1...
  13. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..A series of phase I/II trials are proposed: 1) Phase II study of bicalutamide/leuprolide, 2) Phase I/II study with Sugen-6668, 3)Phase I/II study with an endothelin receptor antagonist...
  14. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
    ..Subjects will be randomly assigned to leuprolide or bicalutamide (150 milligrams by mouth daily) for 12 months...
  15. ENSEMBLE MODEL OF STRESS ACTH-ADRENAL AXIS
    Johannes Veldhuis; Fiscal Year: 2005
    ....
  16. THE AGING GH AXIS IN POSTMENOPAUSAL WOMEN
    Johannes Veldhuis; Fiscal Year: 2005
    ..An enhanced knowledge base should aid ultimately in formulating more innovative preventive and interventional strategies to limit hyposomatotropism in older and/or estrogen-deficient humans. ..
  17. ACTIONS OF ESTROGEN IN MATURING GRAAFIAN FOLLICLES
    Johannes Veldhuis; Fiscal Year: 2005
    ..Understanding such fundamental interactions is important to the rational design of alternative strategies to interrupt normal and rescue impaired steroidogenesis in the maturing Graafian follicle and corpus luteum. ..
  18. Novel Active Repressor Model of Human LDL-Receptor Regulation
    Johannes Veldhuis; Fiscal Year: 2008
    ..This would represent a new treatment approach for patients with atherosclerotic disease. [unreadable] [unreadable] [unreadable] [unreadable]..
  19. Mechanistic bases for age-related androgen deficiency
    Johannes Veldhuis; Fiscal Year: 2007
    ..Knowing why testosterone falls should help foster new and safer ways to prevent the problem. [unreadable] [unreadable] [unreadable]..
  20. Ensemble Disruption of the GnRH-LH-Testosterone Axis
    Johannes Veldhuis; Fiscal Year: 2007
    ..Expected corollary outcomes are enhanced diagnosis, assessment and management of more subtle pathophysiology of the male gonadal axis in puberty and adulthood. ..
  21. Analytical Reconstruction of Feedback Signaling in Aging Men
    Johannes Veldhuis; Fiscal Year: 2008
    ..The present proposal develops a general biomathematical framework for dissecting otherwise observed pathways that control hormone output in aging, stress and disease. [unreadable] [unreadable] [unreadable]..
  22. SEX HORMONES AND BODY FLUID REGULATION
    NINA STACHENFELD; Fiscal Year: 2003
    ..temporarily inhibit sex steroid hormone secretion in young women with the gondotropin releasing-hormone analog, leuprolide acetate, and then isolate the effects of estrogen and progesterone on body water and sodium regulation by adding ..
  23. Estrogen & Progesterone Effects on Orthostatic Tolerance
    NINA STACHENFELD; Fiscal Year: 2010
    ..We also expect that the data in these studies will provide a basis to study the impact of sex hormones on diseases related to compromised peripheral circulation, such as hypertension, Raynaud's phenomenon and diabetes ..
  24. NUCLEOPROTEINS IN MAMMALIAN SPERMATOGENESIS
    Marvin Meistrich; Fiscal Year: 2006
    ..Thus they provide a well-defined model system for study of human infertility. ..
  25. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
    ..The PI has enlisted the support of consultants who will assist in this important evaluation. The results of this analysis will be critical in allocating health care resources. ..
  26. PHYSIOLOGY OF ESTROGEN'S MOOD EFFECT IN MENOPAUSAL WOMEN
    Hadine Joffe; Fiscal Year: 2007
    ..Such training will lay the foundation for a career of clinical investigation into the physiology of perimenopausal depression and the impact of hot flushes on sleep, mood, and quality-of-life. ..
  27. PSYCHOBIOLOGY OF ESTROGEN RECEPTOR MODULATORS
    Mark Wilson; Fiscal Year: 2003
    ..These data will provide not only a better understanding of the biology of SERMs but will also help clinicians and patients evaluate of these compounds on behavioral health. ..
  28. Effects of ovarian suppression on substrate metabolism
    MICHAEL TOTH; Fiscal Year: 2007
    ..Women will be randomized to receive the gonadotropin-releasing hormone agonist leuprolide acetate or placebo...
  29. Skeletal muscle contractile dysfunction in heart failure
    MICHAEL TOTH; Fiscal Year: 2009
    ..Our findings will also provide information regarding the utility of resistance exercise training to improve single muscle fiber function, as well as whole muscle performance and whole body physical function in heart failure patients. ..
  30. SKELETAL MUSCLE PROTEIN METABOLISM IN HEART FAILURE
    MICHAEL TOTH; Fiscal Year: 2003
    ..These experiments will provide new information regarding the pathophysiological mechanisms responsible for the loss of skeletal muscle mass and strength in heart failure patients. ..
  31. Neuroendocrine mediation of socially induced anovulation
    Mark Wilson; Fiscal Year: 2009
    ..This project will clarify the neuroendocrine mechanisms mediating socially-induced gonadotropin deficiency and will thus enhance the ability of health providers to diagnose and treat FHCA in women. ..
  32. The Molecular Basis of Ovarian Testosterone Production
    Robert Rosenfield; Fiscal Year: 2004
    ..The overall goal of this proposal is to understand the factors regulating the production of testosterone in women, particularly in their ovaries. ..
  33. FREE PLASMA SEX HORMONE AND ANDROGEN ACTION
    Robert Rosenfield; Fiscal Year: 2001
    ....
  34. SKELETAL MUSCLE PROTEIN METABOLISM IN HEART FAILURE
    MICHAEL TOTH; Fiscal Year: 2001
    ..These experiments will provide new information regarding the pathophysiological mechanisms responsible for the loss of skeletal muscle protein quality and quantity in heart failure patients. ..
  35. Population-Based Reference Ranges for Testosterone
    VASAN S RAMACHANDRAN; Fiscal Year: 2010
    ..These steps will facilitate the development of rational criteria for classifying men into androgen-deficient and androgen-replete categories. ..
  36. Amyloid-beta: The Alternate Hypothesis
    Mark Smith; Fiscal Year: 2007
    ..Completion of the proposed studies will help determine the role of Aft and, more importantly, guide future therapeutic targets. [unreadable] [unreadable]..
  37. Regulation of the von Hippel-Lindau Protein
    Paul Corn; Fiscal Year: 2007
    ..abstract_text> ..
  38. DST and Suicide Prediction
    Elizabeth Young; Fiscal Year: 2003
    ....
  39. BIOLOGY OF COMORBID DEPRESSION AND ANXIETY
    Elizabeth Young; Fiscal Year: 2001
    ..The results of these studies will provide data on whether the biology of these disorders support the nosological distinction between panic disorder, pure major depression and major depression with co-morbid panic disorder. ..
  40. SARCOPENIA--TESTOSTERONE DOSE RESPONSE IN OLDER MEN
    Shalender Bhasin; Fiscal Year: 2002
    ....
  41. Combined Chemoprevention Using a Nanotechnology-based Therapeutic System
    Sunil Prabhu; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  42. Cell Cycle Inhibitors in Alzheimer Disease
    Mark Smith; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  43. Growth Hormone Secretory Dynamics in Peripubertal Girls
    Steven Pincus; Fiscal Year: 2002
    ..In particular, collaborations with pharmaceutical companies who manufacture growth hormone. ..
  44. Impact of intermittent hypoxia on ventilatory drive and apnea severity
    JASON HAROLD MATEIKA; Fiscal Year: 2010
    ..This treatment could be particularly useful in individuals who suffer from mild or moderate forms of OSA when used in conjunction with other potential innovative therapies. ..
  45. Pycnogenol for Treatment of Arm Lymphedema
    Paul Hutson; Fiscal Year: 2004
    ..In summary, the successful completion of this research can be expected to provide an alternative therapy and new instruments for treating and measuring lymphedema. ..
  46. Mechanisms of Testosterone Effects on Body Composition
    Shalendar Bhasin; Fiscal Year: 2007
    ..abstract_text> ..
  47. Testosterone:Physical Function in Men on Hemodialysis
    Shalender Bhasin; Fiscal Year: 2004
    ..Therefore, if successful, this study should help identify a therapeutic intervention that might improve physical function and reduce disability in men with end stage renal disease. ..
  48. ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASIS
    Dan Theodorescu; Fiscal Year: 2005
    ..abstract_text> ..
  49. Treatment Outcomes of Vascular Depression
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..The proposed trial will provide information of value to the practitioner and also provide data to build a more comprehensive model of the prognostic impact of frontal-subcortical brain changes on the outcome of late-life depression. ..
  50. HPA Axis in Depression and Anxiety
    Elizabeth Young; Fiscal Year: 2005
    ....
  51. COOPERATIVE MULTICENTER REPRODUCTIVE MEDICINE NETWORK
    Bruce Carr; Fiscal Year: 2004
    ..In summary, the reproductive endocrinology research team is experienced in multi- center clinical trials and is committed to collaborative participation consistent with the goals of the RMU network. ..
  52. Development of Inventory of Depressive Symptomatology
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
  53. TESTOSTERONE REPLACEMENT & PHYSICAL FUNCTION IN HIV+MEN
    Shalender Bhasin; Fiscal Year: 2005
    ..This study should help identify a therapeutic intervention that might improve physical function in HIV-infected men with weight loss, and enhance our understanding of the mechanisms by which testosterone stimulates muscle accretion. ..
  54. Sleep, Metabolic, and Cardiovascular Dysfunction in PCOS
    David Ehrmann; Fiscal Year: 2006
    ..parameters, women with PCOS will be randomized to an 8-week treatment phase with pioglitazone or depot leuprolide plus estrogerdprogestin replacement or placebo...
  55. Cognitive Effects of Opioids in Older Adults
    Monique Cherrier; Fiscal Year: 2006
    ..abstract_text> ..
  56. HOX GENE EXPRESSION IN HUMAN ENDOMETRIUM
    Hugh Taylor; Fiscal Year: 2007
    ..These studies will further characterize the molecular mechanisms by which HOX expression is related to normal and pathologic endometrial development. ..
  57. Effect of GnRH antagonist on primordial follicle survival in the primate ovary
    DOUGLAS DANFORTH; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  58. Role of 5-alpha Reductase in Testosterone Actions
    Shalendar Bhasin; Fiscal Year: 2007
    ..abstract_text> ..
  59. FEMALE SEXUAL AROUSAL: CLITORAL AND VAGINAL PHYSIOLOGY
    Abdulmaged Traish; Fiscal Year: 2003
    ....
  60. Testosterone Modulation of Response to Phosphodiesterase Inhibitors
    Shalendar Bhasin; Fiscal Year: 2009
    ....